Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00539071 · ClinicalTrials.gov registry record · Phase 4
High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
A Phase 4 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
NCT00539071 is a Phase 4 study that has completed, run by Northwestern University. The registered enrollment target is 160 participants.
The verdict
NCT00539071, a Phase 4 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of this study is to look at two doses of long-acting injectable risperidone (Risperdal Consta). The study will use a usual dose of Risperdal Consta (50 mg given every two weeks) or a higher dose (75 mg-100 mg given every two weeks) to see which one is better at improving symptoms of schizophrenia or schizoaffective disorder.
Interventions
- DRUG long-acting injectable risperidone
- DRUG long acting injectable risperidone, Conventional Dose Group
- DRUG long acting injectable risperidone, High Dose Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2008-03 |
| Est. Completion | 2012-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00539071
The ClinicalTrials.gov registry entry for NCT00539071 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which long-acting injectable risperidone is the first listed.
NCT00539071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00539071 about?
NCT00539071 is a clinical study titled "High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone". The purpose of this study is to look at two doses of long-acting injectable risperidone (Risperdal Consta). The study will use a usual dose of Risperdal Consta (50 mg given every two weeks) or a higher dose (75 mg-100 mg given every two weeks) to see which one is better at improving symptoms of schi...
What is the current status of trial NCT00539071?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2008-03. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00539071?
The interventions under investigation include: long-acting injectable risperidone (DRUG), long acting injectable risperidone, Conventional Dose Group (DRUG), long acting injectable risperidone, High Dose Group (DRUG).
Who is sponsoring clinical trial NCT00539071?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.